Research programme: NCAM agonists - ENKAM PharmaceuticalsAlternative Names: Dennexin; Fibroblast growth factor (FGF) receptor agonists - ENKAM; NCAM mimetic peptides; NCAM mimetics; P2; P2-peptide; Plannexin; TBI therapeutics - ENKAM; Traumatic brain injury therapeutics - ENKAM
Latest Information Update: 28 May 2011
At a glance
- Originator ENKAM Pharmaceuticals A/S
- Class Peptides
- Mechanism of Action Fibroblast growth factor receptor agonists; Neural cell adhesion molecule agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Brain injuries